The present invention relates to a class of melanocortin MCR4 agonists of
general formula (I) 1
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined
herein and especially to selective MCR4 agonist compounds, to their use
in medicine, to compositions containing them, to processes for their
preparation and to intermediates used in such processes.
